MONTREAL, Oct. 28, 2013 /CNW Telbec/ - Milestone Pharmaceuticals Inc., a
cardiovascular drug development company, today announced that it has
initiated a Phase 1 clinical trial with MSP-2017. MSP-2017 is a novel
short-acting calcium channel antagonist that has demonstrated
modulation of conductivity at the AV node of the heart in preclinical
models. Milestone is initially developing MSP-2017 as a nasal spray
that could be self-administered at home by patients for an initial
potential treatment of paroxysmal supraventricular tachycardia (PSVT).
The Phase 1 single ascending dose study will evaluate the safety,
tolerability and pharmacokinetics of MSP-2017 in healthy volunteers
using a crossover design to assess two intranasal formulations of
"MSP-2017 addresses an unmet medical need because there are no
short-acting products for terminating PSVT episodes in the at-home
setting, requiring most patients developing this arrhythmia to have to
go to the emergency room for treatment with intravenous medications.
The treatment could provide patients with an alternative to catheter
ablation and might also be used in lieu of chronic pharmacologic
therapy for patients with mild to moderate symptoms," said Philippe
Douville, PhD, Chief Executive Officer of Milestone Pharmaceuticals.
"Adenosine, the most widely used short-acting drug, can only be
administered intravenously in a clinical setting. A short-acting
product for PSVT episodes that could be self-administered would change
the pharmacological paradigm for PSVT treatment and give patients the
option to treat these events in the unmonitored setting and hopefully
improve their quality of life," added Philip Sager, MD, FACC, Chief
Medical Advisor for Milestone Pharmaceuticals.
The Phase 1 study is a randomized, double-blind, placebo-controlled
crossover study to assess single ascending doses of two intranasal
formulations of MSP-2017 in healthy adult volunteers in Australia. The
program advanced into Phase 1 clinical testing following successful
preclinical studies with MSP-2017.
About Milestone Pharmaceuticals
Milestone is a drug development company developing novel small molecule
therapeutics based on clinically validated mechanisms for
cardiovascular diseases. Milestone's lead product is a novel and potent
short-acting calcium channel antagonist for the systemic treatment of
transient cardiovascular conditions such as atrial arrhythmias and
angina. The Company has assembled a world-class scientific advisory
board of key opinion leaders with significant cardiovascular expertise
in cardiology, regulatory affairs, and drug development. For more
information, please visit www.milestonepharma.com
SOURCE: Milestone Pharmaceuticals Inc.
For further information:
Philippe Douville, Chief Executive Officer, (514) 496-3220. firstname.lastname@example.org